Malaria is one of the greatest killers in Africa, Asia, South America, and even in the world at large. It is an epidermic that claims over three million lives every year, with over a million lives from Africa.
Although the ecological and climatic conditions of Africa favor the wide spread of the disease, it still cannot be isolated from poverty. The poor, who cannot afford to take adequate preventive and quick corrective measures are the most vulnerable to this epidermic disease. This is evident from the prevalence of this disease in Africa, Asia, and South America. These continents consist of countries that are performing poorly economically and citizens living in abject poverty.
Important socio-economic differentials exist in access to malaria interventions, increasing the vulnerability of the poorest, majority of who reside in these aforementioned continents.
The symptoms of malaria do not change, whether in Europe or America, Africa or Asia. Considering the economic status of Africa, a new and expensive malaria drug can be tested in other continents and on confirmation of its potency, deployed to Africa for use. The African government, and other health organizations can make efforts on drastic subsidization of these drugs for the people. The extremely indigent can be given for free with the help of international organizations.
